Skip to main content
2024
Newsletter

This issue of RADAR provides an overview of medicines recently revised on the Pharmaceutical Benefits Scheme (PBS) including:

  • Nirmatrelvir and ritonavir (Paxlovid®) and molnupiravir (Lagevrio®) for COVID-19 (amended PBS listing)
  • Type 2 diabetes mellitus (T2DM) medicines (amended PBS restrictions).

Learn more about RADAR.

About RADAR

RADAR provides independent, timely and evidence-based information to health professionals about new and revised listings on the Pharmaceutical Benefits Scheme (PBS). This information assist prescribers to make informed prescribing decisions and provide optimal care.

2024
Newsletter

This issue includes items on prevention, oral health, medication safety, patient engagement, COVID-19, and more. Also covered are the latest from Australian Prescriber, BMJ Quality & Safety, Pediatric Quality & Safety, Public Health Research & Practice and International Journal for Quality in Health Care.

Read the latest edition of Person-centred Care Insights.

2024
Newsletter

Read the latest edition of Person-centred Care Insights. Dive into person-centred care! Browse innovative projects from our network. Find new resources, tools, training opportunities, upcoming events, and the latest publications on person-centred care.

2024
Publication, report or update

This Communiqué provides an update on the second meeting of the National Sepsis Oversight Group (Oversight Group). It may be used by members to update their nominating organisations and other key agencies about the National Sepsis Program Extension (Program Extension).

This advisory describes the minimum requirements for Action 5.13 for health service organisations establishing a comprehensive plan.

2024
Newsletter

This issue includes items on newly released Women's Health Focus Report and revised Heavy Menstrual Bleeding Clinical Care Standard, the updated High Risk Medicines eLearning module, the Global Patient Safety Report 2024, design creativity in healthcare improvement, mental health, healthcare safety, hospital acquired complications (HACs), stakeholder engagement, falls, aged care, COVID-19, and more.

Today the Commission has released national trend data in a new report suggesting that women may be turning from hysterectomy to less invasive treatments for heavy menstrual bleeding, a condition that affects one in four Australian women.

We are excited to announce that the National Medicines Symposium 2024 will be held on 19 November 2024.

Back to top